PINL:GRPOF - Post by User
Post by
FormerSupporteron Feb 03, 2021 10:36am
138 Views
Post# 32457756
Enjouca
EnjoucaGood news on finding a path forward to move QIXLEEF in Canada. Hopefully they can reach this timeline and start commercialization in Canada sooner then later. It would be nice to be able to get more details about the process and capital required to launch Enjouca in Canada.
Keep in mind that with this Tetra is now playing in the LP's world of medical cannabis. They will have to fight the LP's for market space. If the science supports QIXLEEF/Enjouca then this would give Tetra a great angle.
I wonder if this move will spark interest in Aphria/Tilray. Knowing that this is a product that can potentially take market share away from Tilray.
As a result, Tetra's strategy is to launch QIXLEEF™ under the trademark, ENJOUCA™ as a medical cannabis product within those territories using its robust clinical package.
Tetra needed to strategically create distance between QIXLEEF™ and ENJOUCA™. These brands will command different commercial execution, from a supply, reimbursement, and promotional activity standpoint, due to different regulatory requirements. What is very positive is that we will be able to launch ENJOUCA™ in Canada during the second half of 2021. Patients and healthcare professionals will finally have a cannabinoid therapeutic option that is supported by strong evidence" said Dania Scott, ENJOUCA Managing Director.